Migraine News and Research

Latest Migraine News and Research

Botox may offer new hope for patients with low cerebrospinal fluid headaches

A Mayo Clinic case study finds Botox may offer new hope to patients suffering disabling low cerebrospinal fluid headaches. The successful treatment also offers new insight into Botox and headache treatment generally.

15 Apr 2011

Laquinimod drug greatly reduces number of relapses in patients with MS

The drug laquinimod reduced the number of relapses for people with multiple sclerosis, in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9-16, 2011, in Honolulu.

12 Apr 2011

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu.

12 Apr 2011

Investigational drug effective for patients with obesity

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University Medical Center.

11 Apr 2011

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

MAP Pharmaceuticals, Inc. today announced the publication of results from the Phase 3 FREEDOM-301 study of LEVADEX orally inhaled migraine drug in the peer-reviewed journal 'Headache.'

7 Apr 2011

Positive results from Neuros Medical Electrical Nerve Block technology study in chronic pain

Neuros Medical, Inc., a medical device company, announced promising results today from their recently completed feasibility study. The study was the first human test of the Company's patented high frequency Electrical Nerve Block™ technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S. During the study, four of the five patients reported their pain was reduced to zero.

7 Apr 2011

Workers exposed to welding fumes may face risk of developing brain damage

New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

AAN honors Mayo Clinic researcher with John Dystel Prize for MS work

The American Academy of Neurology is awarding the 2011 John Dystel Prize for Multiple Sclerosis Research to Brian G. Weinshenker, MD, of the Mayo Clinic in Rochester, Minnesota and a Fellow with the AAN.

1 Apr 2011

New study suggests link between migraine headaches and PFO in children

Roughly 15% of children suffer from migraines, and approximately one-third of these affected children have migraines with aura, a collection of symptoms that can include weakness, blind spots, and even hallucinations.

31 Mar 2011

Study: Marijuana use may affect cognitive skills in patients with MS

Any possible pain relief that marijuana has for people with multiple sclerosis may be outweighed by the drug's apparent negative effect on thinking skills, according to research published in the March 29, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

29 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010.

24 Mar 2011

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.

23 Mar 2011

POZEN files motion for Treximet patent litigation against Par

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that it has filed a motion for a preliminary injunction seeking to prevent Par Pharmaceuticals, Inc. from launching a generic version of Treximet.

23 Mar 2011

Study: Stem cell transplant may benefit patients with rapidly progressive MS

A long term study reports about the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous stem cell rescue for people with aggressive forms of multiple sclerosis.

22 Mar 2011

BDSI's BEMA drug delivery technology receives Canada patent

BioDelivery Sciences International, Inc. announced the issuance of a patent extending the exclusivity of the BioErodible MucoAdhesive drug delivery technology in Canada from 2017 to 2027. The patent was been reviewed by the Office of Patented Medicines for listing in the Canadian Patent Register and was found eligible for listing.

22 Mar 2011

Researchers baffled with increase in migraine rates

Migraine rates in a comprehensive Norwegian health study have climbed by 1% in a decade -- that may not sound like much, but in the Norwegian context, it means 45,000 more migraine sufferers -- and if the trend were to hold for the European Union, that would be an additional 5 million more people plagued by migraines. Researchers at the Norwegian University of Science and Technology (NTNU) are baffled by the cause of this trend.

21 Mar 2011

Depressed, older people who have a stroke are more likely to be dependent

People who have a stroke are more likely to be dependent if they are depressed, older or have other medical problems, according to a study published in the March 15, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology.

15 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011